167 related articles for article (PubMed ID: 37286171)
1. Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease.
Batzu L; Urso D; Grothe MJ; Veréb D; Chaudhuri KR; Pereira JB
Neurobiol Dis; 2023 Jul; 183():106182. PubMed ID: 37286171
[TBL] [Abstract][Full Text] [Related]
2. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
[TBL] [Abstract][Full Text] [Related]
3. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
[TBL] [Abstract][Full Text] [Related]
4. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
[TBL] [Abstract][Full Text] [Related]
5. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
[TBL] [Abstract][Full Text] [Related]
6. Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.
Thaler A; Kliper E; Maidan I; Herman T; Rosenberg-Katz K; Bregman N; Gurevich T; Shiner T; Hausdorff JM; Orr-Urtreger A; Giladi N; Mirelman A
Brain Topogr; 2018 Nov; 31(6):1029-1036. PubMed ID: 29846835
[TBL] [Abstract][Full Text] [Related]
7. Serum neurofilament light chain in LRRK2 related Parkinson's disease: A five years follow-up.
Nabizadeh F; Mohamadzadeh O; Hosseini H; Rasouli K; Afyouni NE
J Clin Neurosci; 2023 Apr; 110():12-18. PubMed ID: 36780781
[TBL] [Abstract][Full Text] [Related]
8. Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson's disease.
Schumacher J; Kanel P; Dyrba M; Storch A; Bohnen NI; Teipel S; Grothe MJ
Brain; 2023 Dec; 146(12):4964-4973. PubMed ID: 37403733
[TBL] [Abstract][Full Text] [Related]
9. Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease.
Thaler A; Livne V; Rubinstein E; Omer N; Faust-Socher A; Cohen B; Giladi N; Shirvan JC; Cedarbaum JM; Gana-Weisz M; Goldstein O; Orr-Urtreger A; Alcalay RN; Mirelman A
Parkinsonism Relat Disord; 2024 Jun; 123():106970. PubMed ID: 38691978
[TBL] [Abstract][Full Text] [Related]
10. Cognitive profile and 18F-fluorodeoxyglucose PET study in LRRK2-related Parkinson's disease.
De Rosa A; Peluso S; De Lucia N; Russo P; Annarumma I; Esposito M; Manganelli F; Brunetti A; De Michele G; Pappatà S
Parkinsonism Relat Disord; 2018 Feb; 47():80-83. PubMed ID: 29249679
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
12. Progression in the LRRK2-Asssociated Parkinson Disease Population.
Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
[TBL] [Abstract][Full Text] [Related]
13. Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with Parkinson's disease.
Hong JH; Kim YK; Park JS; Lee JE; Oh MS; Chung EJ; Kim JY; Sung YH; Lyoo CH; Lee JH; Kwon DY; Kim HS; Shin HW; Park SA; Park IS; Kim JS; Lee PH; Koh SB; Baik JS; Kim SJ; Ma HI; Kim JW; Kim YJ
J Clin Neurosci; 2017 Feb; 36():108-113. PubMed ID: 27839916
[TBL] [Abstract][Full Text] [Related]
14. Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
Ortega RA; Wang C; Raymond D; Bryant N; Scherzer CR; Thaler A; Alcalay RN; West AB; Mirelman A; Kuras Y; Marder KS; Giladi N; Ozelius LJ; Bressman SB; Saunders-Pullman R
JAMA Netw Open; 2021 Apr; 4(4):e215845. PubMed ID: 33881531
[TBL] [Abstract][Full Text] [Related]
15. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
[TBL] [Abstract][Full Text] [Related]
16. Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the
Saunders-Pullman R; Ortega RA; Wang C; Raymond D; Elango S; Leaver K; Urval N; Katsnelson V; Gerber R; Swan M; Shanker V; Alcalay RN; Mirelman A; Brumm MC; Mejia-Santana H; Coffey CS; Marek K; Ozelius LJ; Giladi N; Marder KS; Bressman SB
Neurology; 2022 Aug; 99(8):e814-e823. PubMed ID: 35995594
[TBL] [Abstract][Full Text] [Related]
17. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
[TBL] [Abstract][Full Text] [Related]
18. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
19. Differences in EEG Event-Related Potentials during Dual Task in Parkinson's Disease Carriers and Non-Carriers of the G2019S-LRRK2 Mutation.
Shkury E; Danziger-Schragenheim S; Katzir Z; Ezra Y; Giladi N; Mirelman A; Maidan I
Sensors (Basel); 2023 Oct; 23(19):. PubMed ID: 37837096
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease.
Pereira JB; Hall S; Jalakas M; Grothe MJ; Strandberg O; Stomrud E; Westman E; van Westen D; Hansson O
Neurobiol Dis; 2020 Jun; 139():104831. PubMed ID: 32145376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
